Atossa Therapeutics: Strategic Advancements in Breast Cancer Treatment Drive Buy Rating
Wall Street analyst Jason McCarthy from Maxim Group maintains a Buy rating on Atossa Therapeutics with a $4.00 price target, citing strategic advancements in breast cancer treatment. The company's low-dose endoxifen program and high-dose endoxifen initiative for metastatic ER+/HER2– breast cancer are key factors. A favorable FDA interaction could boost stock value. McCarthy's optimistic outlook is supported by Atossa's cash position, despite his average return of -14.4% and 33.20% success rate on stocks.
Atossa Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from Maxim Group maintained a Buy rating on the stock and has a $4.00 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Jason McCarthy has given his Buy rating due to a combination of factors surrounding Atossa Therapeutics’ strategic advancements in breast cancer treatment. The company’s focus on the low-dose endoxifen program for breast cancer risk reduction is a significant near-term priority, with the potential for an NDA filing contingent on forthcoming feedback from the FDA. A favorable outcome from this interaction could serve as a crucial catalyst for the company’s stock.
Additionally, Atossa is progressing with its high-dose endoxifen program targeting metastatic ER+/HER2– breast cancer, with plans to file an IND by the end of 2025. This initiative is poised to assess the safety and efficacy of endoxifen, which has shown promise in achieving therapeutic levels more rapidly than the current standard of care, tamoxifen. These developments, coupled with the company’s robust cash position, underpin McCarthy’s optimistic outlook and Buy rating.
McCarthy covers the Healthcare sector, focusing on stocks such as SCYNEXIS, OS Therapies Incorporated, and Neuphoria Therapeutics. According to TipRanks, McCarthy has an average return of -14.4% and a 33.20% success rate on recommended stocks.
